Questions prioritized by the ASH Guideline Panel on Cardiopulmonary and Kidney Disease
| Prioritized questions . |
|---|
| Q1. Should screening ECHO vs no screening be performed to identify PH in asymptomatic patients with SCD? |
| Q2. Should right-heart catheterization vs serial noninvasive monitoring be performed for patients with SCD suspected to have PH based on an abnormal ECHO? |
| Q3. Should targeted therapy for PAH or chronic transfusions vs no targeted therapy or chronic transfusions be used for patients with SCD and right-heart catheterization–defined PAH? |
| Q4. Should screening for abnormal pulmonary function vs no screening be performed for asymptomatic patients with SCD? |
| Q5. Should screening using formal polysomnography (sleep study) for sleep-disordered breathing vs no screening be performed for asymptomatic patients with SCD? |
| Q6. Should angiotensin inhibition vs no angiotensin inhibition be used for patients with SCD and albuminuria? |
| Q7. Should proceeding with renal transplant vs remaining on dialysis be considered for patients with SCD and end-stage renal disease? |
| Q8. Should combination therapy with hydroxyurea and erythropoiesis-stimulating agents vs hydroxyurea alone be used for patients with SCD and nephropathy? |
| Q9. Should the target blood pressure in adults with SCD be ≤130/80 mm Hg vs ≤140/90 mm Hg? |
| Q10. Should indefinite anticoagulation vs short-term (≤6 mo) anticoagulation be used for adults with SCD who have first unprovoked, first provoked, or recurrent provoked VTE? |
| Prioritized questions . |
|---|
| Q1. Should screening ECHO vs no screening be performed to identify PH in asymptomatic patients with SCD? |
| Q2. Should right-heart catheterization vs serial noninvasive monitoring be performed for patients with SCD suspected to have PH based on an abnormal ECHO? |
| Q3. Should targeted therapy for PAH or chronic transfusions vs no targeted therapy or chronic transfusions be used for patients with SCD and right-heart catheterization–defined PAH? |
| Q4. Should screening for abnormal pulmonary function vs no screening be performed for asymptomatic patients with SCD? |
| Q5. Should screening using formal polysomnography (sleep study) for sleep-disordered breathing vs no screening be performed for asymptomatic patients with SCD? |
| Q6. Should angiotensin inhibition vs no angiotensin inhibition be used for patients with SCD and albuminuria? |
| Q7. Should proceeding with renal transplant vs remaining on dialysis be considered for patients with SCD and end-stage renal disease? |
| Q8. Should combination therapy with hydroxyurea and erythropoiesis-stimulating agents vs hydroxyurea alone be used for patients with SCD and nephropathy? |
| Q9. Should the target blood pressure in adults with SCD be ≤130/80 mm Hg vs ≤140/90 mm Hg? |
| Q10. Should indefinite anticoagulation vs short-term (≤6 mo) anticoagulation be used for adults with SCD who have first unprovoked, first provoked, or recurrent provoked VTE? |